Geropharm
Geropharm is the #1 insulin manufacturer in Russia and a top-10 global producer. The Russian biotech company operates full-cycle gene-engineering insulin manufacturing and serves diabetes, neurology, ophthalmology, and gynecology markets across Russia and 14 export countries.
- Company typePrivate
- Founded2001
- HeadquartersSaint Petersburg, Russia
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Geropharm does
Geropharm is a Russian pharmaceutical and biotechnology company founded in 2001 and headquartered in Saint Petersburg. It holds the #1 position in the Russian insulin market and ranks among the TOP-10 global insulin manufacturers. The company employs over 1,600 people and operates across Russia and 14 foreign countries, with a therapeutic focus on endocrinology (insulin and metabolic disease as the core franchise), neurology and psychiatry, ophthalmology, and gynecology. Customers are served through B2B pharmaceutical distribution, including Russian state procurement, pharmacy networks, and government-backed export partnerships.
The technological backbone is full-cycle recombinant DNA biotechnology using proprietary E. coli strains for insulin production, an architecture that makes Russia the fifth country globally with end-to-end gene-engineering insulin manufacturing capability. Manufacturing is anchored at two sites: Obolensk in the Moscow Region, covering approximately 30% of Russian insulin demand, and Pushkin in Saint Petersburg, designed at full capacity to cover 100% of Russian insulin needs. The portfolio spans original medicines, biosimilar recombinant human insulins and insulin analogues, generics, and combination products, supported by a 35-product pipeline that includes Rinsulin, RinFast, RinGlar, Rinformin Long, Evodin (a proprietary DPP-4 inhibitor, evogliptin), and Semavik (semaglutide produced under compulsory license). Four granted patents protect the core insulin-producing strain.
The revenue model is product sales of prescription pharmaceuticals via Russian pharmacy distribution and via authorised distributors and government partnerships in export markets (Uzbekistan, Azerbaijan, Myanmar, and China). Commercial channels include field medical representatives targeting healthcare professionals, physician training programmes with health ministries (notably Uzbekistan since 2022), and government-level engagement at international forums such as SPIEF. In 2025 the company has accelerated international expansion through two flagship moves: the launch of a Russia-China Industrial Biomedicine and Pharmaceutics Institute in Guangzhou with FEFU and Chinese partners, and an insulin localisation partnership with R-Pharm in Azerbaijan.
Geropharm firmographics
Firmographics- Name
- Geropharm
- Legal name
- OOO GEROPHARM (GEROPHARM LTD)
- Website
- https://geropharm.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Geropharm is the #1 insulin manufacturer in Russia and a top-10 global producer. The Russian biotech company operates full-cycle gene-engineering insulin manufacturing and serves diabetes, neurology, ophthalmology, and gynecology markets across Russia and 14 export countries.
- Ownership category
- akta.pro rank
Geropharm industry classification
Industry- Product category
- Insulin Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Endocrinology & Metabolic Specialty Pharmaceuticals (HLAIACAD), Ophthalmology Specialty Pharmaceuticals (HLAIACAK), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE)
Keywords
Where Geropharm is headquartered
LocationHeadquarters
- HQ city
- Saint Petersburg
- HQ country
- Russia
- HQ region
- Europe
Offices4 records
Markets served
Geropharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical Products Sales: Sale of proprietary and biosimilar pharmaceutical products across endocrinology, neurology, psychiatry, ophthalmology, and gynecology therapeutic areas. Pipeline includes 35 products including original medicines, biosimilar recombinant human insulins and insulin analogues, and generics.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
Geropharm product offering
Product offeringCore offering
Geropharm is a Russian biotechnological pharmaceutical manufacturer that develops and produces a portfolio of 35 products including proprietary and biosimilar recombinant human insulins, insulin analogues, oral antidiabetics, neurological, ophthalmological, and gynecological medications. The company operates full-cycle gene-engineering insulin manufacturing from active pharmaceutical ingredient synthesis through finished dosage form at its Obolensk and Pushkin facilities in Russia. It is the #1 player in the Russian insulin market and ranks among the TOP-10 global insulin manufacturers.
Product overview
GEROPHARM is an international rapidly growing biotechnological company and the leader in the Russian insulin market, ranked among the TOP-10 global insulin manufacturers. The company operates a portfolio of 35 products spanning original medicines, biosimilar recombinant human insulins, insulin analogues, and generics. Core offerings include multiple insulin formulations covering all therapeutic segments: short-acting insulins (Rinsulin® R, RinFast®), intermediate-acting (Rinsulin® NPH), premixed combinations (Rinsulin® Mix 30/70, RinFast® Mix 30, RinLis® Mix 25), and long-acting analogues (RinGlar®, Insulin Degludec in development). Oral antidiabetics include Rinformin® Long (metformin ER) and Evodin® (DPP-4 inhibitor), alongside obesity treatment Semavik® (semaglutide) and pipeline therapy Sejaro® (tirzepatide). Neurological portfolio features original products Cortexin® and its pediatric formulation, Recognan®, Levetinol®, and Memantinol® for CNS conditions. Ophthalmological offerings center on Retinalamin®, the only Russian retinoprotective agent. Gynecological product Pineamin® addresses menopausal syndrome. The company maintains full-cycle manufacturing capabilities producing from substance synthesis through finished dosage forms, with Rinsapen® II reusable pen-injector providing drug delivery for its insulin cartridge products.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Rinsulin substance ahead of international standards in degree of purification from impurities
- +2 more outcomes
Companies that use Geropharm
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
Geropharm technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
Feature3 records
Geropharm partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- R-Pharm AzerbaijancoreStrategic partnership for localisation of insulin production in Azerbaijan. Agreement provides for localisation of secondary packaging processes for three insulin products (RinGlar, RinFast, RinFast Mix) at R-Pharm facilities in Baku. First production campaign completed and products entered commercial market. R-Pharm facility covers 4.6 hectares with state-of-the-art technology producing over 250 million units annually.
- Far Eastern Federal University (FEFU)coreLaunched first International Industrial Biomedicine and Pharmaceutics Institute in Guangzhou, China. Institute provides platform for educational programmes in biomedicine and healthcare; trains professionals for high-tech manufacturing. Studies start September 2025 at Xinhua University campuses. Plans for mirror biomedicine laboratories at FEFU and Xinhua University.
- Guangzhou Xinhua UniversitycorePartner in International Industrial Biomedicine and Pharmaceutics Institute in Guangzhou. Host institution for joint educational programmes in biomedicine and healthcare starting September 2025 at campuses in Guangzhou and Dongguan.
- Guangzhou Trauer Biotechnology Co.coreCo-founder of International Industrial Biomedicine and Pharmaceutics Institute alongside GEROPHARM, FEFU, and Xinhua University. Represents Chinese business component of the joint institute structure.
- Guangzhou PharmaceuticalsminorOne of the leading pharmaceutical corporations in Guangzhou supporting the Russia-China Industrial Biomedicine Institute. Partnership offers internships at modern facilities and jobs to alumni; supports commercialisation of scientific research.
- Ministry of Health of UzbekistancoreSupported diabetes prevention, diagnosis, and management initiatives. In 2022, initiated physician training programme at endocrinology centres to prepare trainers for diabetes schools in all regions of Uzbekistan. GEROPHARM has been exporting products to Uzbekistan since 2021 with five insulin products approved.
Scale indicators9 records
Recent moves8 records
Expansion highlights7 records
Geropharm competitors and assessment
Company assessmentBroad incumbents
- Novo Nordisk: Global leader in diabetes care and insulin manufacturing, originator of major insulin analogues and Ozempic (semaglutide). Directly comparable as a full-cycle insulin and GLP-1 producer with which Geropharm competes in technology and product categories.
- Sanofi: Global pharmaceutical company with a major diabetes franchise (Lantus, Toujeo, insulins) and broader cardiometabolic portfolio. Comparable to Geropharm as a multinational insulin and cardiometabolic drug manufacturer.
- Eli Lilly: Major global insulin manufacturer (Humalog, Humulin, Basaglar) and originator of Mounjaro (tirzepatide). Comparable as a producer of insulin analogues and next-generation incretin therapies overlapping with Geropharm's pipeline.
Direct peers
- Biocon: Indian biopharmaceutical company focused on biosimilar insulins and affordable diabetes care for emerging markets. Closely comparable to Geropharm as a biosimilar insulin manufacturer serving cost-sensitive markets with a similar export-oriented model.
- Pharmstandard: Largest Russian pharmaceutical manufacturer with broad branded and generic portfolio across multiple therapeutic areas. Comparable as a domestic Russian pharma peer competing in the same state procurement channels and therapeutic segments as Geropharm.
- BIOCAD: Russian biotechnology company developing biosimilars, generics, and original biologics. Comparable as a domestic biotech peer in biosimilar development and Russian state-aligned biopharma production.
- Generium: Russian biopharmaceutical manufacturer specializing in biosimilars, gene therapy, and blood products. Comparable as a domestic full-cycle biotech manufacturer competing for Russian state procurement and biosimilar market share.
Regional players
- R-Pharm: Major Russian pharmaceutical manufacturer and Geropharm's localization partner in Azerbaijan for insulin secondary packaging. Comparable as a domestic Russian pharma peer and the operational partner for Geropharm's CIS export model.
- Gulf Pharmaceutical Industries (Julphar): MENA-region pharmaceutical manufacturer producing insulins, biosimilars, and generics primarily for the Middle East and Africa. Comparable to Geropharm as a regional full-cycle insulin and biopharma producer with an export-led growth model.
- Polysan: Russian pharmaceutical manufacturer with branded products in neurology, psychiatry, and endocrinology (including Cytoflavin). Comparable to Geropharm as a domestic Russian pharma peer overlapping in neurology, cardiology, and metabolic therapy areas.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Geropharm social profiles
Digital presenceGeropharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Geropharm leadership team
Management profileNumber of profiles
Geropharm funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Geropharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Geropharm
What does Geropharm do?
Geropharm is a Russian biotechnological pharmaceutical manufacturer that develops and produces a portfolio of 35 products including proprietary and biosimilar recombinant human insulins, insulin analogues, oral antidiabetics, neurological, ophthalmological, and gynecological medications. The company operates full-cycle gene-engineering insulin manufacturing from active pharmaceutical ingredient synthesis through finished dosage form at its Obolensk and Pushkin facilities in Russia. It is the #1 player in the Russian insulin market and ranks among the TOP-10 global insulin manufacturers.
Is Geropharm a public or private company?
Geropharm is a private company. It is classified as unknown and is currently operating.
When was Geropharm founded?
Geropharm was founded in 2001. It employs 1,001 to 5,000 people.
Where is Geropharm based?
Geropharm is headquartered in Saint Petersburg, Russia, in the Europe region.
How does Geropharm make money?
One revenue line is on record: pharmaceutical Products Sales.
Who are Geropharm's main competitors?
Broad incumbents on record are Novo Nordisk, Sanofi and Eli Lilly. Direct peers are Biocon, Pharmstandard, BIOCAD and Generium. Regional players are R-Pharm, Gulf Pharmaceutical Industries (Julphar) and Polysan.
Does Geropharm have an API?
No public API is recorded for Geropharm.
What industry is Geropharm in?
Geropharm's product category is Insulin Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.